Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.68 |
| ▸ | CCKAR | P32238 | 12/20 | 0.48 |
| ▸ | CCKBR | P32239 | 12/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13577532 | 0.99 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL15002881 | 0.95 | GLP1R (0.62) | GLP1RCCKARCCKBR | |
| SCHEMBL15579830 | 0.94 | GLP1R (0.72) | GLP1RCCKARCCKBR | |
| SCHEMBL19786713 | 0.94 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL21242874 | 0.94 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL17127184 | 0.94 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL21242938 | 0.94 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL21242749 | 0.94 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL21242892 | 0.94 | GLP1R (0.69) | GLP1RCCKARCCKBR | |
| SCHEMBL14805474 | 0.94 | GLP1R (0.69) | GLP1RCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160347812-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-12-01 | — | — | US | disclosed |
| US-20150374794-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-20130079278-A1 | Novel Glucagon Analogues | NOVO NORDISK A/S (DK) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374794-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | GLP1R, GIPR, GCGR | GLP1R 1/4885CCKAR 24/4885CCKBR 21/4885 |
| US-20130079278-A1 | Novel Glucagon Analogues | GLP1R, GCG, GCGR | GLP1R 1/4885CCKAR 64/4885CCKBR 34/4885 |
| US-20160347812-A1 | Novel Glucagon Analogues | GLP1R, GCG, GCGR | GLP1R 1/4885CCKAR 64/4885CCKBR 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.